EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Diagnostic and Prognostic Value of cfDNA Concentration and Fragmentation in Prostate Cancer

Marta Victoria Lorenzo-Sánchez, José Miguel Giménez-Bachs, María Granada Picazo-Martínez, María José Donate-Moreno, Carlos Martínez-Sánchiz, María Amalia Tárraga-Honrubia, Sonsoles Navarro-Jiménez, Óscar Legido-Gómez, Antonio Santiago Salinas-Sánchez iD

The Prostate · 2026

DOI: 10.1002/pros.70090 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Prostate, 2026. Verfasst von Marta Victoria Lorenzo-Sánchez und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Hospital and University Complex of Albacete, Albacete, Spain. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Biomarkers, Tumor, Cell-Free Nucleic Acids, DNA Fragmentation. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the value of circulating free DNA (cfDNA) in prostate cancer (PCa) by cfDNA assay and analysis of plasma and urinary cfDNA fragmentation to determine the usefulness of this parameter for risk staging and tumor progression monitoring. Materials and Methods A prospective, longitudinal study was conducted with 143 individuals, including a control group and a cohort of patients with PCa at different stages: localized, metastatic hormone‐sensitive (mHSPC), and metastatic castration‐resistant (mCRPC). Plasma and urine samples were collected to measure the concentration, fluorescence units (FU), and cfDNA fragmentation, correlating them with clinical and pathological variables.

Results

Plasma cfDNA levels were higher in patients with PCa than in control subjects (14.3 ng/mL vs. 4.2 ng/mL, p = 0.04) and even higher in metastatic disease than in localized (20.8 ng/mL vs. 3.6 ng/mL, p < 0.001). The fragmentation size of plasma cfDNA was smaller in metastatic PCa (168.7 base pairs) than in localized PCa (172.8 base pairs, p < 0.001), suggesting that shorter fragments are associated with more aggressive disease. Following systemic treatment, the patients decreased cfDNA levels (8.3 ng/mL vs. 4.9 ng/mL, p = 0.027) and plasma FU (35.2 vs. 12.9, p < 0.001). In urine, differences were only observed in patients who progressed to CRPC than in those who remained HSPC (261.8 ng/mL vs. 43.5 ng/mL, p = 0.046).

Conclusions

The assay and analysis of plasma and urinary cfDNA fragmentation may provide useful biomarkers for PCa diagnosis and follow‐up, particularly when differentiating between localized and metastatic disease. These findings are promising, but further research is required to determine their potential utility in clinical risk stratification and treatment monitoring.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsBiomarkers, TumorCell-Free Nucleic AcidsDNA FragmentationHumansMaleAgedProspective StudiesMiddle AgedPrognosisLongitudinal StudiesAged, 80 and overDisease ProgressionProstatic Neoplasms, Castration-Resistant

Stichwörter der Autor:innen

DNAcell‐free DNA (cfDNA)fragmentationliquid biopsiesprostate cancerprostate cancer diagnosis

Substanzen

Biomarkers, TumorCell-Free Nucleic Acids

Autor:innen und Institutionen

  • Department of Urology, Hospital and University Complex of Albacete, Albacete, Spain.
  • Experimental Research Unit, Hospital and University Complex of Albacete, Albacete, Spain.
  • Department of Urology, General Hospital of Hellín, Albacete, Spain.
  • School of Medicine of Albacete, Universidad de Castilla la Mancha, Albacete, Spain.

ORCID-Profile: Antonio Santiago Salinas-Sánchez

Zitieren

APA

Lorenzo-Sánchez, M. V., Giménez-Bachs, J. M., Picazo-Martínez, M. G., Donate-Moreno, M. J., Martínez-Sánchiz, C., Tárraga-Honrubia, M. A., Navarro-Jiménez, S., Legido-Gómez, Ó., & Salinas-Sánchez, A. S. (2026). Diagnostic and Prognostic Value of cfDNA Concentration and Fragmentation in Prostate Cancer. The Prostate. https://doi.org/10.1002/pros.70090

Vancouver

Lorenzo-Sánchez MV, Giménez-Bachs JM, Picazo-Martínez MG, Donate-Moreno MJ, Martínez-Sánchiz C, Tárraga-Honrubia MA, et al. Diagnostic and Prognostic Value of cfDNA Concentration and Fragmentation in Prostate Cancer. The Prostate. 2026. doi:10.1002/pros.70090

BibTeX
@article{LorenzoSnchez2026,
  author = {Lorenzo-Sánchez, Marta Victoria and Giménez-Bachs, José Miguel and Picazo-Martínez, María Granada and Donate-Moreno, María José and Martínez-Sánchiz, Carlos and Tárraga-Honrubia, María Amalia and Navarro-Jiménez, Sonsoles and Legido-Gómez, Óscar and Salinas-Sánchez, Antonio Santiago},
  title = {Diagnostic and Prognostic Value of cfDNA Concentration and Fragmentation in Prostate Cancer},
  journal = {The Prostate},
  year = {2026},
  doi = {10.1002/pros.70090}
}
Kostenlos starten →